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ABSTRACT 
IDENTIFICATION OF NOVEL ALLOSTERIC REGULATORS OF HUMAN 
ERYTHROCYTE PYRUVATE KINASE 
Shilpa S. Kharalkar, M. Pharm. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University 
Virginia Commonwealth University, 2006 
Director: Donald J. Abraham, Ph.D. 
Professor and Director ISBDD 
Department of Medicinal Chemistry 
Erythrocyte pyruvate kinase (R-PK) is a key glycolytic enzyme catalyzing 
the transphosphorylation of phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP 
respectivel$'. The substrate PEP and product pyruvate of this reaction are involved in a 
number of energetic and biosynthetic pathways; hence a tight regulation of R-PK activity 
is crucial not only for glycolysis, but also for the entire cellular metabolism. Deficiency 
of R-PK is one of the most common enzymatic defects of RBC, and may be caused by 
mutations of the PK-LR (pyruvate kinase liver red blood cell) gene 31Z2. Clinically, R-PK 
deficiency manifests itself as a chronic life-long hemolysis ranging from very mild or 
fully compensated anemia to life-threatening neonatal anemia and pronounced jaundice. 
... 
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Current treatment options are limited to continuous blood transfusions and splenectomy. 
Thus, there is an urgent need for medications to counter R-PK deficiency without 
resorting to these complicated procedures. Our aim is to identify novel allosteric 
modifiers of R-PK using a combination of computational studies and enzyme activity 
assays. Such compounds could be of medical interest. 
Human R-PK was expressed in DH-5a cells and was purified by the procedure 
reported by Wang et a1 57. However, this method gave a very low yield of R-PIS (5mgIL). 
In an attempt to increase the yield, we expressed R-PK in Rosetta strain cells. Further, 
addition of His-tag to the protein's N-terminus simplified purification to a one step Ni- 
NTA (Nickel- nitrilotriacetic acid) column resulting in a 6-fold increase in the yield. 
Computational methods were applied to identify small molecules that bind to the 
allosteric activator fructose 1,6-bisphosphate (FBP) binding site of R-PK to identify 
compounds that could interact with the protein. The software UNITY, as present in the 
molecular modeling software Sybyl was used to perform 3D searches against the 
National Cancer Institute (NCI) chemical database. From these searches we obtained 29 
hits that were subjected to further computational analysis. The small molecules were 
docked into the FBP binding site of R-PK with different docking methods inclucding 
FlexX, GOLD and energy minimization. The energy scoring function of HINT was then 
applied to analyze the interactions between the docked molecules and R-PK. Compounds 
with highest HINT score were requested fiom NCI and were subjected to further kinetic 
analysis to identify possible allosteric effectors of R-PK. 
xiv 
In the kinetic analysis, we en~ployed a lactate dehydrogenase (LDH) coupled 
spectrophotometric assay to determine the activity of R-PK in the presence of these 
compounds. The steady state kinetics of R-PK gave a typical S-shaped curve that fitted a 
signloidal function indicative of allosterism. All the kinetic parameters of our enzyme 
were in excellent agreement with native R-PK activity as previously reported5, 57. R-PK 
activity in the presence of the analyzed compounds revealed both activators and 
inhibitors of R-PK. X-ray crystallographic analysis of R-PK in the presence of FBP and 
the identified small molecule effectors are currently in progress. These experiments were 
initiated to reveal the binding site of the compounds in R-PK, allowing for further 
optimization of the starting phannacophores and syntheses of new molecular entities for 
enhanced allosteric activity. 
In conclusion, we have developed a simple and efficient method for the 
expression and purification of R-PK. Using computational screening and HINT analysis 
we have also identified several compounds that interact with R-PK and kinetic analysis 
revealed both activators and inhibitors of the protein. Crystals of R-PK in the presence of 
effectors have been obtained and identification of the binding site on R-PK is under 
investigation. R-PK effectors discovered in this study could prove to be lead compounds 
for developing medications for the treatment of anemia and other disorders arising from 
R-PK malfunction. 
INTRODUCTION 
A. Pyruvate Kinase 
Glycolysis is the sequence of reactions that converts glucose into pyruvate with 
the concomitant production of a relatively small amount of ATP. Pyruvate kinase (PK: 
ATP: pyruvate 2-o-phosphotransferase, EC 2.7.1.40) is a key enzyme of this pathway that 
catalyzes the transphosphorylation of phosphoenolpyruvate (PEP) and ADP to pyruvate 
and ATP respectively 3,4. This conversion takes place in two steps: initially, the phospho 
moiety of PEP is transferred to a Mg-ADP complex via an enolate intermediate; 
following, stereo-specific protonation and tautomerization yields the keto form of 
pyruvate. The enzyme requires divalent and monovalent ions, including Mn2', Mg2', H' 
and K' ions for activity 677. The pyruvate kinase reaction is shown in Figure 1 and the 
glycolysis pathway is shown in Figure 2. 
PK is an important regulatory enzyme and plays a dual role in glycolysis as it 
generates ATP in the cell, and is also involved in the regulation of glucose metabolism. 
As seen in Figure 1 and 2, the PK catalyzed reaction is bidirectional; however under 
physiological conditions the formation of energy rich ATP molecules is favored. The 
activation of PK increases the ATP concentration in cell whereas its down regulation 
allows for accumulation of phosphometabolite pools preceding the PK reaction that can 
































































































